Actively Recruiting

Phase 1
Phase 2
Age: 25Years - 60Years
FEMALE
NCT06610773

HUC-MSC for Treatment of High-risk HPV Infection

Led by Shanghai East Hospital · Updated on 2024-09-24

60

Participants Needed

1

Research Sites

131 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the safety and initial effectiveness of human umbilical cord mesenchymal stem cells in HPV clearance.

CONDITIONS

Official Title

HUC-MSC for Treatment of High-risk HPV Infection

Who Can Participate

Age: 25Years - 60Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 25-60 with a sexual history of more than 2 years
  • Confirmed high-risk HPV infection by HPV-24 test
  • Diagnosed with persistent high-risk HPV infection
  • Not participating in other clinical trials or using anti-HPV drugs recently
  • Negative pregnancy test and agree to use effective contraception during and for 6 months after the study if fertile
  • Voluntarily agree to participate and sign informed consent
Not Eligible

You will not qualify if you...

  • Preparing for pregnancy, pregnant, or breastfeeding
  • Diagnosed with high-grade squamous intraepithelial lesion (HSIL) or cervical cancer
  • Previously vaccinated against HPV
  • History of severe drug allergies or allergies to stem cell products or biologics
  • Previous cervical physical therapy or related surgery
  • Severe immune dysfunction or serious diseases of cardiovascular, liver, kidney, nervous, hematopoietic systems, malignant tumors, or mental diseases
  • Recent use of antiviral drugs, immunosuppressants, immunomodulators, or steroid hormones affecting the immune system
  • Acute genital or pelvic inflammation
  • Participation in other drug clinical trials within the past 3 months
  • Other conditions deemed inappropriate by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Shanghai East Hospital, Tongji University School of Medicine

Shanghai, Shanghai Municipality, China, 200120

Actively Recruiting

Loading map...

Research Team

J

Jingjing Liu, M.D,.PH.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

HUC-MSC for Treatment of High-risk HPV Infection | DecenTrialz